Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma.

The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Hepatitis B virus (HBV) infection remains an urgent global health concern, affecting hundreds of millions of people and significantly heightening the risk ...

Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...

Hepatitis B can lead to liver disease. But we can prevent and manage this viral infection. Here’s what we know about the ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...

The following is a summary of "Impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced ...

Chronic hepatitis B (CHB) remains a major global health challenge, with functional cure achieved in only a small subset of patients. Current oral antiviral agents effectively suppress viral ...

Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

The American Gastroenterological Association (AGA) has released an updated clinical practice guideline on the prevention of ...